SCHEMBL29352177

SCHEMBL29352177

COc1ccc(C2=C(N3CCOCC3)C(=O)N(c3ccc(Cl)c(Cl)c3)C2=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
RAD51 Q06609 11/20 1.00
RAD1 O60671 2/20 1.00
BCL2A1 Q16548 5/20 0.66
MAPT P10636 4/20 0.55
HSD17B10 Q99714 2/20 0.50
MAPK1 P28482 1/20 0.49
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
BCL2 P10415 1/20 0.48
ALOX12 P18054 1/20 0.48
BID P55957 1/20 0.48
BCL2L1 Q07817 1/20 0.48
BCL2L2 Q92843 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15758872 1.00 RAD51 (1.00) RAD51RAD1BCL2A1MAPTHSD17B10
SCHEMBL17208336 0.88 RAD51 (0.78) RAD51RAD1BCL2A1MAPTHSD17B10
SCHEMBL15758657 0.88 RAD51 (0.78) RAD51RAD1BCL2A1MAPTHSD17B10
SCHEMBL15758474 0.86 RAD51 (0.75) RAD51RAD1BCL2A1MAPTHSD17B10
SCHEMBL17202955 0.86 RAD51 (0.75) RAD51RAD1BCL2A1MAPTHSD17B10
SCHEMBL15758183 0.85 RAD51 (0.74) RAD51RAD1BCL2A1MAPTHSD17B10
SCHEMBL17201949 0.85 RAD51 (0.74) RAD51RAD1BCL2A1MAPTHSD17B10
SCHEMBL15758221 0.84 RAD51 (0.72) RAD51RAD1BCL2A1MAPTHSD17B10
SCHEMBL15758589 0.81 RAD51 (0.67) RAD51RAD1BCL2A1MAPTALDH1A1
SCHEMBL15758723 0.79 RAD51 (1.00) RAD51RAD1BCL2A1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250345443-A1 PHARMACEUTICAL COMPOUND AND USE THEREOF DUALITY BIOLOGICS SUZHOU CO LTD (CN) 2025-11-13 US claimed
US-20250320192-A1 DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME DEUTERX LLC (US) 2025-10-16 US claimed
US-12446430-B2 Display panel with dummy pixel space, display device and display driving method BEIJING BOE OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) 2025-10-14 US claimed
US-12413931-B2 Method and system for optimizing the position of a user equipment Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2025-09-09 US claimed
EP-4610261-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF Neushen Therapeutics (Shanghai) Co., Ltd (CN) 2025-09-03 EP claimed
US-12373929-B2 Underwater image color restoration method and apparatus, and underwater video color restoration method and apparatus ARASHI VISION INC. (CN) 2025-07-29 US claimed
CN-120192324-A Heterocyclic compound, pharmaceutical composition and application 上海医药集团股份有限公司 2025-06-24 CN claimed
CN-120084320-A SINS/RDOSB joint positioning method and system based on periodic sound source field 东南大学南通海洋高等研究院 2025-06-03 CN claimed
CN-119762233-A Investment optimization method and device 中国长城科技集团股份有限公司 2025-04-04 CN claimed
CN-119670601-A Temperature distribution prediction method suitable for horizontal well multistage fracturing process 北京信息科技大学 2025-03-21 CN claimed
US-20230242504-A1 DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME DEUTERX LLC (US) 2023-08-03 US claimed
EP-4014610-B1 POSITIONING FRAUNHOFER GES FORSCHUNG (DE) 2023-07-19 EP claimed
US-11535603-B1 Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same DEUTERX, LLC (US) 2022-12-27 US claimed
CN-115459751-A High-voltage switch assembly based on SiC MOSFET series connection 重庆大学 2022-12-09 CN claimed
US-20220286812-A1 Method and System for Optimizing the Position of a User Equipment Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2022-09-08 US claimed
EP-4014610-A1 POSITIONING Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2022-06-22 EP claimed
US-11363963-B2 Method and device for determining the hydration, fitness and nutrition status of a human body CELLA MEDICAL, INC. 2022-06-21 US claimed
CN-114088433-A Track circuit analog load equipment 卡斯柯信号有限公司 2022-02-25 CN claimed
CN-114048842-A Main shaft reliability prediction method of gradient descent optimization neural network 沈阳航空航天大学 2022-02-15 CN claimed
CN-109746766-B Method and system for determining temperature field of wear zone of rear cutter face of integral end mill 哈尔滨理工大学 2022-01-25 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242504-A1 DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME EGLN3, HPGDS, EGLN2 RAD51 429/4885RAD1 2212/4885BCL2A1 2442/4885
US-20250320192-A1 DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME EGLN3, HPGDS, EGLN2 RAD51 429/4885RAD1 2212/4885BCL2A1 2442/4885
US-20250345443-A1 PHARMACEUTICAL COMPOUND AND USE THEREOF SLC10A1, FURIN, SELL RAD51 4829/4885RAD1 4885/4885BCL2A1 4637/4885
US-11535603-B1 Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same EGLN3, HPGDS, EGLN2 RAD51 429/4885RAD1 2212/4885BCL2A1 2442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.